CESCA THERAPEUTICS INC. (NASDAQ:KOOL) Files An 8-K Other Events
Item 8.01. Entry into a Material Definitive
Agreement.
On May 26, 2017, Cesca Therapeutics Inc. (the Company) entered
into a Sixth Amended and Restated Technology License and Escrow
Agreement with Cbr Systems, Inc. (CBR) with an effective date of
May 15, 2017 (the Amendment). The Amendment amends and restates
in its entirety the Fifth Amended and Restated Technology License
and Escrow Agreement entered into in October 22, 2015 by the
Company and CBR (the Prior Agreement). The Amendment, among other
things, amends the Prior Agreement by changing the circumstances
that constitute a Default thereunder and by conditioning the
circumstances under which CBR may, upon a default by Cesca,
purchase licensed products from other manufacturers and
suppliers.
The foregoing description of the Amendment is incomplete and is
qualified by reference to the full text of the Agreement, which
is attached as Exhibit 10.1 hereto and incorporated herein by
reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
10.1 |
Sixth Amended and Restated Technology License and Escrow |
*Confidential treatment has been requested for certain
confidential portions of this exhibit to Rule 24b-2 under the
Exchange Act. In accordance with Rule 24b-2, these confidential
portions have been omitted from this exhibit and filed separately
with the SEC.
About CESCA THERAPEUTICS INC. (NASDAQ:KOOL)
Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company’s therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood. CESCA THERAPEUTICS INC. (NASDAQ:KOOL) Recent Trading Information
CESCA THERAPEUTICS INC. (NASDAQ:KOOL) closed its last trading session up +0.02 at 3.10 with 18,268 shares trading hands.
